The T7 mScript™ Standard mRNA Production System provides all enzymes and enzyme-related reagents for making 5'-capped, 3'-polyadenylated mRNA. This mScript Kit includes modules for (i) in vitro transcription of linear double-stranded DNA templates using the mScript T7 Enzyme Solution, the canonical nucleotides ATP, CTP, GTP and UTP, (ii) enzymatic capping of the RNA using ScriptCap™ Capping Enzyme System (for making mRNA with a Cap 0 cap structure), (iii) ScriptCap™ 2'-O-Methyltransferase (for optionally making mRNA with a Cap 1 cap structure) and (iv) A-Plus™ Poly(A) Polymerase for adding a 3'-poly(A) tail. Post-transfection, capped and tailed mRNA has increased stability and translation efficiency in most eukaryotic cell lines. The mScript System improves upon existing capping methods by ensuring virtually 100% transcript capping, all caps in the proper orientation and the ability to produce large amounts of capped RNA at a reasonable cost. This mRNA is suitable for use in transfection and microinjection experiments as well as in vitro translation systems.
The mission of CELLSCRIPT™ is to provide the best products and technologies for making and using RNA for translation in cells for clinical research and therapeutics.
Current products include kits for in vitro transcription, 5' RNA capping using either a cap analog or capping enzymes, and 3' RNA polyadenylation, as well as all-in-one kits for making capped, poly(A)-tailed mRNA for translation in cells.
CELLSCRIPT™ recently introduced INCOGNITO™ RNA Transcription Kits for in vitrosynthesis of RNA that contains modified nucleosides, such as pseudouridine (Ψ) and/or 5-methylcytidine (m5C) in place of the corresponding U or C canonical nucleosides (Figure 1). These kits are so-named because the capped, polyadenylated and nucleoside-modified RNA products (called "INCOGNITO mRNAs") are disguised so they do not induce innate immune responses to the same extent as the corresponding unmodified mRNAs when transfected into mammalian cells that express a variety of RNA sensors.